peptech implements antibody

Sydney - Friday - March 16: (RWE Australian Business News) -
Australian biotechnology company, Peptech Limited (ASX: PTD; AIM: PTDx)
today announced the implementation of a proprietary antibody based
therapeutic technology platform, named Synhumanisation, which provides a
competitive advantage by enabling therapeutic drugs to be developed
against multiple medical targets.
Synhumanisation is centred on the use of human-like antibody
sequences in place of mouse sequences in order to avoid potentially
harmful immune responses in humans. The Synhumanisation platform will
result in increased discovery of patentable new antibody products.